Establishment Labs (NASDAQ:ESTA) Director Sells $2,790,066.06 in Stock

Key Points

• Director Quiros Juan Jose Chacon sold 42,642 shares on April 23 at an average price of $65.43 for $2,790,066.06, leaving him with 1,139,862 shares (a 3.61% ownership decrease valued at about $74.58M).
• Those trades are part of a recent string of insider sales by Quiros totaling roughly $9.63M across March–April (multiple transactions listed with sizes and prices).
• Shares traded down about 1.2% to $65.47; the company has a $1.92B market cap, negative P/E (-37.63) despite a quarter where EPS beat estimates and revenue rose 45.2% YoY, and analysts show an average target of $86.86 (consensus: Moderate Buy).

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) Director Quiros Juan Jose Chacon sold 42,642 shares of Establishment Labs stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $65.43, for a total transaction of $2,790,066.06. Following the transaction, the director directly owned 1,139,862 shares of the company's stock, valued at $74,581,170.66. The trade was a 3.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Monday, April 27th, Quiros Juan Jose Chacon sold 2,180 shares of Establishment Labs stock. The stock was sold at an average price of $66.26, for a total transaction of $144,446.80.
• On Friday, April 24th, Quiros Juan Jose Chacon sold 30,178 shares of Establishment Labs stock. The stock was sold at an average price of $65.78, for a total transaction of $1,985,108.84.
• On Tuesday, April 14th, Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock. The stock was sold at an average price of $65.23, for a total transaction of $2,446,125.00.
• On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The stock was sold at an average price of $60.08, for a total transaction of $214,786.00.
• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The shares were sold at an average price of $60.39, for a total transaction of $2,048,730.75.

Establishment Labs Trading Down 1.2%

Shares of ESTA traded down $0.81 during trading hours on Monday, reaching $65.47. 280,264 shares of the company traded hands, compared to its average volume of 500,208. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of -37.63 and a beta of 1.08. Establishment Labs Holdings Inc. has a 12-month low of $28.89 and a 12-month high of $83.31. The company has a current ratio of 3.04, a quick ratio of 2.00 and a debt-to-equity ratio of 10.51. The stock's fifty day moving average price is $66.33 and its 200 day moving average price is $65.35.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.13. The firm had revenue of $64.62 million during the quarter, compared to analyst estimates of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The business's revenue was up 45.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.19) earnings per share. Sell-side analysts forecast that Establishment Labs Holdings Inc. will post -0.86 earnings per share for the current year.

Institutional Trading of Establishment Labs

A number of hedge funds have recently added to or reduced their stakes in ESTA. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Establishment Labs by 20.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company's stock worth $2,335,000 after acquiring an additional 9,557 shares during the period. Geode Capital Management LLC lifted its stake in Establishment Labs by 1.2% in the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company's stock worth $1,105,000 after acquiring an additional 299 shares during the period. WINTON GROUP Ltd purchased a new stake in Establishment Labs in the second quarter worth about $651,000. Nebula Research & Development LLC lifted its stake in Establishment Labs by 27.9% in the second quarter. Nebula Research & Development LLC now owns 16,214 shares of the company's stock worth $692,000 after acquiring an additional 3,538 shares during the period. Finally, Sei Investments Co. lifted its stake in Establishment Labs by 13.3% in the second quarter. Sei Investments Co. now owns 48,428 shares of the company's stock worth $2,068,000 after acquiring an additional 5,668 shares during the period. 72.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Establishment Labs from a "buy" rating to a "hold" rating in a research note on Saturday, March 28th. BTIG Research boosted their target price on shares of Establishment Labs from $86.00 to $88.00 and gave the company a "buy" rating in a research note on Tuesday, February 24th. Needham & Company LLC boosted their target price on shares of Establishment Labs from $84.00 to $86.00 and gave the company a "buy" rating in a research note on Tuesday, February 24th. Canaccord Genuity Group boosted their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the company a "buy" rating in a research note on Thursday, February 26th. Finally, Citigroup lowered their price objective on shares of Establishment Labs from $81.00 to $74.00 and set a "neutral" rating for the company in a research note on Wednesday, March 11th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $86.86.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.